BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 8044825)

  • 1. Antigen forks: bispecific reagents that inhibit cell growth by binding selected pairs of tumor antigens.
    Ring DB; Hsieh-Ma ST; Shi T; Reeder J
    Cancer Immunol Immunother; 1994 Jul; 39(1):41-8. PubMed ID: 8044825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro tumor growth inhibition by bispecific antibodies to human transferrin receptor and tumor-associated antigens is augmented by the iron chelator deferoxamine.
    Hsieh-Ma ST; Shi T; Reeder J; Ring DB
    Clin Immunol Immunopathol; 1996 Aug; 80(2):185-93. PubMed ID: 8764564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Murine bispecific antibody 1A10 directed to human transferrin receptor and a 42-kDa tumor-associated glycoprotein.
    Shi T; Hsieh-Ma ST; Reeder J; Ring DB
    Clin Immunol Immunopathol; 1996 Feb; 78(2):188-95. PubMed ID: 8625561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding characteristics and antitumor properties of 1A10 bispecific antibody recognizing gp40 and human transferrin receptor.
    Amoroso AR; Clark JI; Litwin S; Hsieh-Ma S; Shi T; Alpaugh RK; Adams GP; Wolf EJ; Ring DB; Weiner LM
    Cancer Res; 1996 Jan; 56(1):113-20. PubMed ID: 8548750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combination of two immunotoxins exerts synergistic cytotoxic activity against human breast-cancer cell lines.
    Crews JR; Maier LA; Yu YH; Hester S; O'Briant K; Leslie DS; DeSombre K; George SL; Boyer CM; Argon Y
    Int J Cancer; 1992 Jul; 51(5):772-9. PubMed ID: 1351885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of hematopoietic progenitor colony growth by a monoclonal antibody against the transferrin receptor: comparison of unconjugated antibody with an immunotoxin containing recombinant ricin A chain.
    Shannon KM; Ring DB; Houston LL; Schaffner V; Naylor J; Torkildson JC; Reid SA; Larrick J
    Int J Cell Cloning; 1990 Sep; 8(5):368-76. PubMed ID: 2230286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a trispecific antibody conjugate that directs two distinct tumor-associated antigens to CD64 on myeloid effector cells.
    Somasundaram C; Sundarapandiyan K; Keler T; Deo YM; Graziano RF
    Hum Antibodies; 1999; 9(1):47-54. PubMed ID: 10331185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design.
    Lee NK; Su Y; Bidlingmaier S; Liu B
    Mol Cancer Ther; 2019 Jun; 18(6):1092-1103. PubMed ID: 30962321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of a novel bispecific antibody that mediates Fcgamma receptor type I-dependent killing of tumor-associated glycoprotein-72-expressing tumor cells.
    Russoniello C; Somasundaram C; Schlom J; Deo YM; Keler T
    Clin Cancer Res; 1998 Sep; 4(9):2237-43. PubMed ID: 9748144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
    Watanabe M; Wallace PK; Keler T; Deo YM; Akewanlop C; Hayes DF
    Breast Cancer Res Treat; 1999 Feb; 53(3):199-207. PubMed ID: 10369066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced therapeutic efficacy against an ovarian tumor xenograft of immunotoxins used in conjunction with recombinant alpha-interferon.
    Pearson JW; Hedrick E; Fogler WE; Bull RL; Ferris DK; Riggs CW; Wiltrout RH; Sivam G; Morgan AC; Groves E
    Cancer Res; 1990 Oct; 50(19):6379-88. PubMed ID: 2144790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice.
    Laske DW; Ilercil O; Akbasak A; Youle RJ; Oldfield EH
    J Neurosurg; 1994 Mar; 80(3):520-6. PubMed ID: 8113865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
    Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
    Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling.
    Diermeier-Daucher S; Ortmann O; Buchholz S; Brockhoff G
    MAbs; 2012; 4(5):614-22. PubMed ID: 22820509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format.
    Shahied LS; Tang Y; Alpaugh RK; Somer R; Greenspon D; Weiner LM
    J Biol Chem; 2004 Dec; 279(52):53907-14. PubMed ID: 15471859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma.
    Waldron NN; Barsky SH; Dougherty PR; Vallera DA
    Target Oncol; 2014 Sep; 9(3):239-49. PubMed ID: 23900680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
    Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
    Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity.
    Ye S; Cohen D; Belmar NA; Choi D; Tan SS; Sho M; Akamatsu Y; Kim H; Iyer R; Cabel J; Lake M; Song D; Harlan J; Zhang C; Fang Y; Wahl AF; Culp P; Hollenbaugh D; Chao DT
    Cancer Immunol Res; 2019 Nov; 7(11):1864-1875. PubMed ID: 31462409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen.
    Dorvillius M; Garambois V; Pourquier D; Gutowski M; Rouanet P; Mani JC; Pugnière M; Hynes NE; Pèlegrin A
    Tumour Biol; 2002; 23(6):337-47. PubMed ID: 12677091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody.
    Huang S; Li F; Liu H; Ye P; Fan X; Yuan X; Wu Z; Chen J; Jin C; Shen B; Feng J; Zhang B
    MAbs; 2018; 10(6):864-875. PubMed ID: 30081724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.